JPMorgan maintained an underweight rating on Dr Reddy’s Laboratories with a target price of Rs 4610. Form 483 observations are likely to result in an overhang, it said.
In the Nifty500 pack, six stocks’ closing prices crossed above their 200-day moving averages (DMA) on September 11, 2026, according to StockEdge’s technical scan data.
The Federal Reserve’s potential rate hike looms over global markets. US 10-year sovereign yields nearing five percent pose a significant challenge. This rise makes emerging
Advertiser Disclosure
Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.
Disclaimer
It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.
The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.
Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003